Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;75(8):1407-1414.
doi: 10.1002/art.42489. Epub 2023 May 18.

Anti-Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody-Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and Repository

Collaborators, Affiliations

Anti-Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody-Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and Repository

Yu Zuo et al. Arthritis Rheumatol. 2023 Aug.

Abstract

Objective: This study aimed to elucidate the presence, antigen specificities, and potential clinical associations of anti-neutrophil extracellular trap (anti-NET) antibodies in a multinational cohort of antiphospholipid (aPL) antibody-positive patients who did not have lupus.

Methods: Anti-NET IgG/IgM levels were measured in serum samples from 389 aPL-positive patients; 308 patients met the classification criteria for antiphospholipid syndrome. Multivariate logistic regression with best variable model selection was used to determine clinical associations. For a subset of the patients (n = 214), we profiled autoantibodies using an autoantigen microarray platform.

Results: We found elevated levels of anti-NET IgG and/or IgM in 45% of the aPL-positive patients. High anti-NET antibody levels are associated with more circulating myeloperoxidase (MPO)-DNA complexes, which are a biomarker of NETs. When considering clinical manifestations, positive anti-NET IgG was associated with lesions affecting the white matter of the brain, even after adjusting for demographic variables and aPL profiles. Anti-NET IgM tracked with complement consumption after controlling for aPL profiles; furthermore, patient serum samples containing high levels of anti-NET IgM efficiently deposited complement C3d on NETs. As determined by autoantigen microarray, positive testing for anti-NET IgG was significantly associated with several autoantibodies, including those recognizing citrullinated histones, heparan sulfate proteoglycan, laminin, MPO-DNA complexes, and nucleosomes. Anti-NET IgM positivity was associated with autoantibodies targeting single-stranded DNA, double-stranded DNA, and proliferating cell nuclear antigen.

Conclusion: These data reveal high levels of anti-NET antibodies in 45% of aPL-positive patients, where they potentially activate the complement cascade. While anti-NET IgM may especially recognize DNA in NETs, anti-NET IgG species appear to be more likely to target NET-associated protein antigens.

Trial registration: ClinicalTrials.gov UL1-TR000457.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Measurement of anti-NET antibodies in 389 aPL-positive patients. A, Schematic illustration of the anti-NET Ab ELISA. B-C, Anti-NET IgG and IgM were measured in the indicated groups; no patients in this cohort had lupus. Patients were grouped based on no criteria manifestations (“aPL positive”), a history of thrombotic manifestations (47 of these 278 patients also had a history of obstetric manifestations), or a history of obstetric manifestations without history of vascular thrombosis. Levels of anti-NET IgG and IgM at 450-nm optical density (OD) were compared to controls by Kruskal–Wallis test corrected for multiple comparisons by Dunn’s method; *p<0.05, **p<0.01, and ****p<0.0001. Horizontal black lines indicate medians and dashed lines indicate 99th percentile cut-offs. D-E, Association between positive anti-NET IgG (E) or IgM (F) and various extra-criteria APS clinical manifestations were assessed by multivariate logistic regression adjusted for demographic variables (age, sex, ethnicity) and aPL profiles.
Figure 2:
Figure 2:
Function and potential antigen specificities of anti-NET antibodies. A, Complement C3d decorating NETs. Control neutrophils were stimulated with PMA to generate NETs, which were then incubated with serum from patients with high (top panels) anti-NET IgM or from healthy controls; scale bars=100 microns. B-D, Autoantibody microarray comparing anti-NET IgG-positive and -negative samples (C-D), and anti-NET IgM-positive and -negative samples (E). Volcano plots demonstrate (in red) antigen specificities that were significantly enriched in the anti-NET-positive groups.

Comment in

References

    1. Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med 2018;378(21):2010–21. - PubMed
    1. Tambralli A, Gockman K, Knight JS. NETs in APS: Current Knowledge and Future Perspectives. Curr Rheumatol Rep 2020;22(10):67. - PubMed
    1. Zuo Y, Yalavarthi S, Gockman K, Madison JA, Gudjonsson JE, Kahlenberg JM, et al. Anti-Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome. Arthritis Rheumatol 2020;72(12):2130–5. - PMC - PubMed
    1. Erkan D, Sciascia S, Bertolaccini ML, Cohen H, Committee AAE. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. Curr Rheumatol Rep 2021;23(6):45. - PMC - PubMed
    1. Ali RA, Gandhi AA, Meng H, Yalavarthi S, Vreede AP, Estes SK, et al. Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome. Nat Commun 2019;10(1):1916. - PMC - PubMed

Publication types

Associated data